-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Given Average Rating of "Hold" by Analysts
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Given Average Rating of "Hold" by Analysts
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX – Get Rating) has been given a consensus recommendation of "Hold" by the six analysts that are covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $20.75.
Several equities analysts have issued reports on the company. Jefferies Financial Group lowered Forma Therapeutics from a "buy" rating to a "hold" rating and dropped their price target for the company from $28.00 to $20.00 in a research note on Friday, September 2nd. HC Wainwright lowered Forma Therapeutics from a "buy" rating to a "neutral" rating and dropped their price target for the company from $53.00 to $20.00 in a research note on Friday, September 2nd. Oppenheimer lowered Forma Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, September 1st. Cantor Fitzgerald lowered Forma Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Thursday, September 1st. Finally, Credit Suisse Group lowered Forma Therapeutics from an "outperform" rating to a "neutral" rating and set a $20.00 target price on the stock. in a research report on Friday, September 2nd.
Get Forma Therapeutics alerts:Hedge Funds Weigh In On Forma Therapeutics
A number of institutional investors have recently modified their holdings of FMTX. Quantbot Technologies LP grew its holdings in Forma Therapeutics by 125.0% during the first quarter. Quantbot Technologies LP now owns 3,600 shares of the company's stock worth $33,000 after buying an additional 2,000 shares in the last quarter. Advisor Group Holdings Inc. grew its holdings in Forma Therapeutics by 17,885.7% during the first quarter. Advisor Group Holdings Inc. now owns 2,518 shares of the company's stock worth $33,000 after buying an additional 2,504 shares in the last quarter. Amalgamated Bank bought a new stake in Forma Therapeutics during the first quarter worth $38,000. US Bancorp DE grew its holdings in Forma Therapeutics by 282.5% during the first quarter. US Bancorp DE now owns 4,341 shares of the company's stock worth $40,000 after buying an additional 3,206 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in Forma Therapeutics by 56.3% during the second quarter. Legal & General Group Plc now owns 10,187 shares of the company's stock worth $70,000 after buying an additional 3,670 shares in the last quarter. 87.39% of the stock is owned by institutional investors and hedge funds.
Forma Therapeutics Stock Performance
Shares of FMTX opened at $19.95 on Tuesday. Forma Therapeutics has a 52-week low of $4.95 and a 52-week high of $24.99. The business's 50 day moving average price is $14.79 and its two-hundred day moving average price is $10.07. The firm has a market cap of $954.61 million, a PE ratio of -4.99 and a beta of -0.31.About Forma Therapeutics
(Get Rating)
Forma Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer.
Recommended Stories
- Get a free copy of the StockNews.com research report on Forma Therapeutics (FMTX)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
Receive News & Ratings for Forma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX – Get Rating) has been given a consensus recommendation of "Hold" by the six analysts that are covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $20.75.
据Marketbeat报道,ForMA治疗控股公司(纳斯达克代码:FMTX-GET评级)已被追踪该公司的六位分析师一致给予“持有”的建议。五位投资分析师对该股的评级为持有建议,一位分析师对该公司发出了买入建议。在去年更新了对该股覆盖范围的分析师中,12个月的平均价格目标是20.75美元。
Several equities analysts have issued reports on the company. Jefferies Financial Group lowered Forma Therapeutics from a "buy" rating to a "hold" rating and dropped their price target for the company from $28.00 to $20.00 in a research note on Friday, September 2nd. HC Wainwright lowered Forma Therapeutics from a "buy" rating to a "neutral" rating and dropped their price target for the company from $53.00 to $20.00 in a research note on Friday, September 2nd. Oppenheimer lowered Forma Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, September 1st. Cantor Fitzgerald lowered Forma Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Thursday, September 1st. Finally, Credit Suisse Group lowered Forma Therapeutics from an "outperform" rating to a "neutral" rating and set a $20.00 target price on the stock. in a research report on Friday, September 2nd.
几位股票分析师已经发布了关于该公司的报告。杰富瑞金融集团在9月2日星期五的一份研究报告中将Forma Treeutics的评级从“买入”下调至“持有”,并将该公司的目标价从28.00美元下调至20.00美元。在9月2日星期五的一份研究报告中,HC Wainwright将Forma Treateutics的评级从“买入”下调至“中性”,并将该公司的目标价从53.00美元下调至20.00美元。奥本海默在9月1日星期四的一份研究报告中将Forma治疗公司的评级从“跑赢大盘”下调至“市场表现”。坎托·菲茨杰拉德在9月1日星期四的一份研究报告中将Forma治疗公司的评级从“增持”下调至“中性”。最后,瑞士信贷集团将Forma Treateutics的评级从表现优于大盘下调至中性,并为该股设定了20.00美元的目标价。在9月2日星期五的一份研究报告中。
Hedge Funds Weigh In On Forma Therapeutics
对冲基金对Forma Treeutics的看法
A number of institutional investors have recently modified their holdings of FMTX. Quantbot Technologies LP grew its holdings in Forma Therapeutics by 125.0% during the first quarter. Quantbot Technologies LP now owns 3,600 shares of the company's stock worth $33,000 after buying an additional 2,000 shares in the last quarter. Advisor Group Holdings Inc. grew its holdings in Forma Therapeutics by 17,885.7% during the first quarter. Advisor Group Holdings Inc. now owns 2,518 shares of the company's stock worth $33,000 after buying an additional 2,504 shares in the last quarter. Amalgamated Bank bought a new stake in Forma Therapeutics during the first quarter worth $38,000. US Bancorp DE grew its holdings in Forma Therapeutics by 282.5% during the first quarter. US Bancorp DE now owns 4,341 shares of the company's stock worth $40,000 after buying an additional 3,206 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in Forma Therapeutics by 56.3% during the second quarter. Legal & General Group Plc now owns 10,187 shares of the company's stock worth $70,000 after buying an additional 3,670 shares in the last quarter. 87.39% of the stock is owned by institutional investors and hedge funds.
多家机构投资者最近调整了对FMTX的持仓。第一季度,Quantbot Technologies LP对Forma Treateutics的持股增加了125.0%。Quantbot Technologies LP现在持有该公司3600股股票,价值3.3万美元,上个季度又购买了2000股。Advisor Group Holdings Inc.在第一季度增持了Forma Treateutics 17885.7%的股份。Advisor Group Holdings Inc.现在持有该公司2,518股股票,价值33,000美元,上个季度又购买了2,504股。合并银行在第一季度购买了Forma Treateutics价值3.8万美元的新股份。第一季度,US Bancorp DE在Forma Treateutics的持股增加了282.5%。US Bancorp DE现在拥有4341股该公司股票,价值4万美元,此前在上个季度又购买了3206股。最后,Legal&General Group Plc在第二季度增持了Forma Treateutics 56.3%的股份。Legal&General Group Plc现在拥有10,187股该公司股票,价值70,000美元,上个季度又购买了3,670股。87.39%的股票由机构投资者和对冲基金持有。
Forma Therapeutics Stock Performance
Forma治疗公司股票表现
About Forma Therapeutics
关于Forma Treateutics
(Get Rating)
(获取评级)
Forma Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer.
Forma治疗控股公司是一家临床阶段的生物制药公司,专注于治疗罕见血液疾病和癌症的新疗法的开发和商业化。其待开发的核心产品包括FT-4202,这是治疗镰状细胞疾病和其他血红蛋白疾病的第一阶段试验;以及FT-7051,用于治疗转移性去势抵抗前列腺癌。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Forma Therapeutics (FMTX)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- 免费获取StockNews.com关于Forma治疗(FMTX)的研究报告
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat:回顾一周9/26-9/30
- 这是买入美光科技的难忘时刻
- 让Paychex股票为您努力工作
- Keurig Dr Pepper与规模更大的竞争对手可口可乐(Coke&Pepsi)相比如何?
Receive News & Ratings for Forma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Forma治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Forma Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧